Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

M. Ross, David; Branford, Susan; F. Seymour, John; P. Schwarer, Anthony; Arthur, Christopher; T. Yeung, David; Dang, Phuong; M. Goyne, Jarrad; Slader, Cassandra; J. Filshie, Robin; K. Mills, Anthony; V. Melo, Junia; L. White, Deborah; P. Grigg, Andrew; P. Hughes, Timothy

doi:10.1182/blood-2013-02-483750

Public

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

Shared by NobleBlocks on Jul 25, 2013 • 12:00 AM UTC

Authors:

David M. Ross

Susan Branford

John F. Seymour

Abstract

Key Points Approximately 40% of patients with undetectable minimal residual disease on imatinib can stop treatment without loss of molecular response. Patients in treatment-free remission still have detectable BCR-ABL DNA several years after stopping imatinib.

Discussions